A PYMNTS Company

US: Merck announces latest push in pharma consolidation

By  |  December 8, 2014

Merck has announced its latest merger plans as the pharmaceutical consolidation spree continues.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    According to reports, Merck is set to acquire Cubist Pharmaceuticals for $8.4 billion. The takeover would boost Merck’s operations in antibiotic research as the medical community focuses more on so-called “superbugs.”

    Warnings from the World Health Organization have called for renewed collaboration to fight the rise in superbugs.

    In a statement, Cubist said it is clear that Merck shares its “commitment to addressing the growing, global problem we are facing” regarding antibiotic resistance.

    Full content: CSMonitor

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.